Business Continuity
Business Continuity
Our laboratory facilities remain operational under the current national restrictions, with a suite of risk...
“SPR Evaluation of Potential Anti-COVID-19 Therapies” poster presentation at ELRIG Drug Discovery Digital 2020
“SPR Evaluation of Potential Anti-COVID-19 Therapies” poster presentation at ELRIG Drug Discovery Digital 2020
ELRIG Drug Discovery Digital 2020 is starting this week, and Dr Clare Box and Dr Kevin Thompson are going to be...
Small Molecules, Binding to AT2 Site on ACE2, Unlikely to Prevent COVID-19 Spike Protein Binding
Small Molecules, Binding to AT2 Site on ACE2, Unlikely to Prevent COVID-19 Spike Protein Binding
Angiotensin II and SARS-CoV-2 ‘spike’ protein bind to independent sites on angiotensin converting enzyme 2. We used...
COVID-19 Decoy: ACE2 in Solution “Decoys” Spike Protein, Inhibiting Binding to Surface Bound ACE2
COVID-19 Decoy: ACE2 in Solution “Decoys” Spike Protein, Inhibiting Binding to Surface Bound ACE2
Using the Biacore Surface Plasmon Resonance (SPR) technique, we have quantified the kinetic receptor binding...
Contact Us
This site is protected by reCAPTCHA. The information you supply will be processed in accordance with the General Data Protection Regulation (EU & UK). For further details, please refer to our Privacy Policy.
Copyright © 2024 Gifford Bioscience Limited
Privacy Policy